Verified Clinical Trials, LLC and Celerion today announced their partnership in the fight against multiple simultaneous clinical trial enrollment in the medical research industry. With the poor economy and intensified recruitment techniques, the medical research industry has seen a tremendous increase in ‘professional’ research participants enrolling in multiple clinical trials simultaneously. This problem has infiltrated into not only healthy participant clinical trials, but all phases of research involving all disease entities.

Dr. Mitchell Efros, President and CEO of Verified Clinical Trials , along with his team of research professionals, developed Verified Clinical Trials, a comprehensive and unique research participant database registry to enhance the safety and quality of both early and late stage clinical trials globally. The system is designed for wide scale deployment for every major Contract Research Organization (CRO) and research site globally, to assist in the goal for improved participant safety and data integrity.

“We specifically chose to partner with Celerion, a leader in innovative early stage clinical research solutions, as a key part of our research and development strategy. Celerion has the largest Phase I bed capacity globally and sets the standard to protect their research participants and enhance data integrity,” stated Dr. Efros.

“This is a very exciting time for Verified Clinical Trials as we further develop our innovative processes and strengthen our network with the goal of improving clinical participant safety and research data quality,” said Dr. Efros. “Celerion intends to have clinical participants ‘verified’ through the Verified Clinical Trials system to ensure that only qualified participants proceed into screening, thereby saving the Sponsor and sites time and money.”

Verified Clinical Trials plans to have nearly all of the most recognized CROs utilizing their system in 2012. Additionally, Verified Clinical Trials continues to enlist a significant cohort of the world's largest pharmaceutical companies. In addition to verifying a research participant is not involved in any other phase of clinical research simultaneously, Verified Clinical Trials offers many other unique value added services for both early and late phase sites to reduce overall cost of the trial and reduce liabilities.

“It is great news for the entire clinical research community that Verified Clinical Trials is boosting its presence and will have major affiliates in so many locations,” said Phil Bach, Vice President of Global Clinical Research at Celerion. “The implementation of the Verified Clinical Trials solution at Celerion supports our commitment to apply rigorous standards to protect the safety of participants and enhance data integrity for Sponsors. This implementation sets a standard in the industry to continue to improve clinical research and bring new drugs to the market place.”

Verified Clinical Trials has also secured its presence in later phase trials with major pharmaceutical companies.

About Verified Clinical Trials (VCT)

Verified Clinical Trials (VCT) was developed by experts active in the clinical research community to proactively improve clinical research participant safety and data quality in clinical research trials. Verified Clinical Trials defines itself as the world's leader in the field of database registries in clinical trial research, and is the only clinical research database registry designed specifically to enhance the quality of both early and late phase trials and has the scalability to reach all sites nationally as well as on a global level. Verified Clinical Trials offers numerous other value added services to the clinical research site, CRO, and Pharmaceutical Sponsor, that prove invaluable with regards to financial and legal issues and liabilities. For more information, visit www.verifiedclinicaltrials.com.

About Celerion

Celerion is the premier provider of innovative early stage clinical research solutions. From facilities strategically located around the world, advanced scientific and technological expertise is applied to clinical research (over 730 beds in Phases 0, I and IIa, NDA-enabling clinical pharmacology, ADME), clinical pharmacology sciences, bioanalytical services (discovery through late stage), and drug development services. Celerion has a full spectrum of resources to meet the needs of the pharmaceutical, biotechnology and generic industries for Phase 0 through IIa proof-of-concept studies. For more information, visit www.celerion.com